Anesthesia Medical News about Neuromuscular block

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Reversal of neuromuscular block
British Journal of Anesthesia, 05/26/09

Srivastava A et al. - Sugammadex is ineffective in antagonizing the benzylisoquinolinium NMBAs. The dose should be adjusted according to the degree of residual block: sugammadex 16 mg kg–1 for immediate reversal; 4–8 mg kg–1 for antagonizing profound block (post-tetanic count 1–2); and 2 mg kg–1 to antagonize moderate block (when T2 is detectable). As yet, the extent of any side-effects that may occur with this new antagonist is not fully known, although rarely adverse cardiovascular effects (hypotension, hypertension, prolonged QT interval) have already been reported.

<< Previous
When Fiberoptic Intubation Fails in Patients with Unstable...

Next >>
Patient-Controlled-Analgesia Analgesimetry and Its Problems